Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
Hypothyroidism II: Pathophysiology01:23

Hypothyroidism II: Pathophysiology

Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism·2026
Same author

Unilateral Graves' disease: a rare presentation of autoimmune hyperthyroidism.

BMJ case reports·2026
Same author

Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026
Same author

Tirzepatide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Delayed-onset central adrenal insufficiency following adjuvant pembrolizumab therapy for renal cell carcinoma.

BMJ case reports·2026
Same author

Ectopic ACTH-dependent Cushing syndrome due to mature ovarian teratoma.

BMJ case reports·2026

Related Experiment Video

Updated: Jun 2, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled

Naseem Eisa1, Omar Barood2

  • 1Community Health Partners, Fresno, California.

AACE Endocrinology and Diabetes
|June 1, 2026
PubMed
Summary

Randomized controlled trials show no increased thyroid cancer risk with incretin-based therapies, such as glucagon-like peptide-1 receptor agonists. However, limited data necessitates continued long-term surveillance for these diabetes treatments.

Keywords:
GLP-1 receptor agonistdrug safetymeta-analysisrandomized controlled trialthyroid cancertirzepatide

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Related Experiment Videos

Last Updated: Jun 2, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Area of Science:

  • Endocrinology and Metabolism
  • Oncology
  • Clinical Trials Methodology

Background:

  • The link between incretin-based therapies (GLP-1 RAs, GIP/GLP-1 RAs) and thyroid cancer risk is debated.
  • Conflicting results from observational studies necessitate evidence from randomized controlled trials (RCTs).

Purpose of the Study:

  • To assess the association between incretin-based therapies and thyroid cancer incidence.
  • Utilize data exclusively from randomized controlled trials for robust analysis.

Main Methods:

  • Systematic review and meta-analysis adhering to PRISMA guidelines.
  • Searched PubMed, EMBASE, and ClinicalTrials.gov for relevant RCTs with at least 26 weeks of follow-up.
  • Extracted data, assessed risk of bias (Cochrane Risk of Bias 2), and performed meta-analysis using a random-effects model.
  • Assessed certainty of evidence using the GRADE framework.

Main Results:

  • Included 15 RCTs with 84,237 participants; 28 thyroid cancer events in incretin-based therapy groups, 15 in control groups.
  • Meta-analysis revealed no statistically significant association between incretin-based therapies and thyroid cancer risk (OR 1.52, 95% CI 0.86-2.68).
  • Evidence certainty was rated as very low due to significant imprecision from rare events.

Conclusions:

  • Current RCT evidence does not support an increased thyroid cancer risk with incretin-based therapies.
  • Limitations in follow-up duration and event imprecision preclude ruling out a clinically significant risk.
  • Long-term surveillance is recommended to monitor for potential risks.